Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY TARDBP cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated ...read more
Immunocytochemistry/ Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Analysis using the DyLight 550 conjugate of NB110-55376. Staining of Human iPS derived neurons, fixed in 4% formaldehyde solution. The ...read more
Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in HeLa WCE.
Immunocytochemistry/ Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in MCF-7 cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and ...read more
This TARDBP antibody is useful for Immunocytochemistry/Immunofluorescence and Western blot analysis. In Western blot a band is seen at ~45 kDa, representing the human TARDBP protein. In ICC/IF a nuclear signal is present in MCF-7 cells. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
45 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
TARDBP (tar-DNA binding protein of 43) is a nucleic acids binding protein that regulates the process of transcription and splicing. Localized mainly in the nucleus, TARDBP is ubiquitously expressed with higher expression levels in pancreas, placenta, lung, genital tract and spleen, and has been suggested to implicate in microRNA biogenesis, cellular apoptosis as well as proliferation. TARDBP controls CFTR splicing and promotes CFTR exon 9 skipping by associating with UG repeated motifs in polymorphic region near 3'-splice site of this exon leading to aberrant splicing linked to pathological features typical of cystic fibrosis. TARDBP can repress HIV-1 transcription by binding to the HIV-1 long terminal repeat. Moreover, it stabilizes the low molecular weight neurofilament mRNA through a direct interaction with the 3' UTR. TARDBP was originally identified as a major protein component of the ubiquitin immuno-positive inclusions which are the pathologic substrate of common forms of ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia), and later, it was found that TARDBP gene mutations are inherited in an autosomal dominant manner in familial/sporadic ALS. TARDBP has also been involved in other neurodegenerative such as Alzheimer's and Parkinson's disease.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
ECL, 2 min exposure, positive control = SH5Y5 cells overexpr TDP-43, negative control = non-transgenic mouse
Antibody detects in non-transgenetic mouse and in transgenetic TDP-43 sample a fragment at 60 kDa. However, 45 kDa fragment is only detected in TDP-43 mouse sample. For a good signal exposure time must be at least 20 min.
Product General Protocols
View specific protocols for TDP-43/TARDBP Antibody (NB110-55376):